Waters Corporation (FRA:WAZ)
Germany · Delayed Price · Currency is EUR | Market Cap | 31.36B +63.4% |
| Revenue (ttm) | 3.27B +26.4% |
| Net Income | 390.14M -31.5% |
| EPS | 5.98 -37.5% |
| Shares Out | n/a |
| PE Ratio | 80.39 |
| Forward PE | 24.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 317.40 |
| Previous Close | 317.40 |
| Day's Range | 316.80 - 317.40 |
| 52-Week Range | 235.00 - 352.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Waters
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, p... [Read more]
Financial Performance
In 2025, Waters's revenue was $3.17 billion, an increase of 6.99% compared to the previous year's $2.96 billion. Earnings were $642.63 million, an increase of 0.75%.
Financial numbers in USD Financial StatementsNews
Waters Transcript: Jefferies Global Healthcare Conference 2026
Double-digit growth was driven by new products, recurring revenue, and strong pharma performance, especially in China and India. Integration efforts are yielding commercial and operational synergies, with accelerated product launches and localization supporting future gains. Pricing improvements and innovation in mass spectrometry and antibodies are set to drive continued growth.
Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% ...
Waters price target raised to $435 from $415 at HSBC
HSBC raised the firm’s price target on Waters (WAT) to $435 from $415 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
Waters price target raised to $400 from $370 at BofA
BofA raised the firm’s price target on Waters (WAT) to $400 from $370 and keeps a Neutral rating on the shares. Diagnostic tools have rallied almost 10% in the last…
Waters assumed with an Outperform at Wolfe Research
Wolfe Research assumed coverage of Waters (WAT) with an Outperform rating and $425 price target The firm stated in a research note on Life Science Tools & Diagnostics that the…
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Ide...
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease sign...
Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Waters price target raised to $350 from $330 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Waters (WAT) to $350 from $330 and keeps a Hold rating on the shares.
Waters price target raised to $425 from $400 at Barclays
Barclays raised the firm’s price target on Waters (WAT) to $425 from $400 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings…
Waters price target raised to $387 from $362 at Baird
Baird raised the firm’s price target on Waters (WAT) to $387 from $362 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results. Published…
Waters price target raised to $345 from $330 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Waters (WAT) to $345 from $330 and keeps a Neutral rating on the shares.
Waters price target raised to $385 from $345 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Waters (WAT) to $385 from $345 and keeps a Hold rating on the shares. The firm updated its model…
Waters price target raised to $375 from $330 at UBS
UBS raised the firm’s price target on Waters (WAT) to $375 from $330 and keeps a Neutral rating on the shares.
Waters CEO highlights China as key innovation source in the biopharma market
Waters CEO Udit Batra highlighted China as a global biopharmaceutical powerhouse. He said that innovation has fueled a rapid expansion of contract manufacturers moving into full drug development.
Waters raises annual profit forecast as biosciences unit drives growth
Lab equipment maker Waters raised its annual profit forecast on Tuesday after beating quarterly estimates, driven by robust demand for drug development tools and the strong performance of its biosci...
Waters Earnings Call Transcript: Q1 2026
Strong Q1 performance with double-digit organic growth, robust execution in acquired businesses, and 20% adjusted EPS growth led to raised 2026 revenue and EPS guidance. Integration and synergy realization are ahead of plan, with new product launches and China localization supporting future growth.
Waters Slides: Q1 2026
Waters has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Waters Earnings release: Q1 2026
Waters released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Waters Quarterly report: Q1 2026
Waters has published its Q1 2026 quarterly earnings report on May 5, 2026.
Waters raises FY26 EPS view to $14.40-$14.60 from $14.30-$14.50
Consensus $14.38. Sees FY26 revenue $6.41B-$6.46B, consensus $6.42B. Batra continued: “As we look ahead, we are raising our guidance to reflect the increased momentum we are seeing across our business...
Waters reports Q1 adjusted EPS $2.70, consensus $2.31
Reports Q1 revenue $1.27B, consensus $1.2B. “Thanks to the hard work of our teams, we delivered an excellent first quarter as a combined company,” said Udit Batra, President & Chief…
Waters sees Q2 adjusted EPS $2.95-$3.05, consensus $3.00
Sees Q2 revenue $1.62B-$1.63B, consensus $1.62B.
Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
First Quarter 2026 Highlights Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acqui...
Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m.